Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 12 September 2025

Sec. Gynecological Oncology

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1697346

This article is part of the Research TopicImmune Predictive and Prognostic Biomarkers in Immuno-Oncology: Refining the Immunological Landscape of CancerView all 46 articles

Correction: CS Ratio is an immune-related prognostic biomarker for cervical cancer

This article is a correction to:

  1. CS Ratio is an immune-related prognostic biomarker for cervical cancer

    1. Read original article
Peiqin Shi&#x;Peiqin Shi1†Wenwen Zhang&#x;Wenwen Zhang2†Qingqing YaoQingqing Yao3Zhanna Yuan,Zhanna Yuan1,4Jiaqi WangJiaqi Wang1Ziye YangZiye Yang3Pengpeng Qu,,*Pengpeng Qu1,3,5*
  • 1Clinical School of Obstetrics and Gynecology Center, Tianjin Medical University, Tianjin, China
  • 2Tianjin Institute of Gynecology Obstetrics, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China
  • 3Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology Obstetrics, School of Medicine, Nankai University, Tianjin, China
  • 4Department of Obstetrics and Gynecology, Tianjin Medical University Baodi Hospital, Tianjin, China
  • 5Department of Gynecological Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Tianjin, China

A Correction on
CS Ratio is an immune-related prognostic biomarker for cervical cancer

By Shi P, Zhang W, Yao Q, Yuan Z, Wang J, Yang Z and Qu P (2025). Front. Oncol. 15:1547529. doi: 10.3389/fonc.2025.1547529

Authors “Peiqin Shi” and “Wenwen Zhang” were erroneously omitted as equal contributing author.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: SPP1, CXCL9, cervical cancer, TCGA, GEO

Citation: Shi P, Zhang W, Yao Q, Yuan Z, Wang J, Yang Z and Qu P (2025) Correction: CS Ratio is an immune-related prognostic biomarker for cervical cancer. Front. Oncol. 15:1697346. doi: 10.3389/fonc.2025.1697346

Received: 02 September 2025; Accepted: 03 September 2025;
Published: 12 September 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Shi, Zhang, Yao, Yuan, Wang, Yang and Qu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Pengpeng Qu, cXUucGVuZ3BlbmdAaG90bWFpbC5jb20=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.